Main Menu

Professor Kamil Kranc

Group Leader

The alt text
Professor Kamil Kranc is the Chair of Haemato-Oncology and Director of the Centre for In Vivo Modelling at The Institute of Cancer Research. His central aim is to discover the key processes governing cancer stem cells in acute myeloid leukaemia, with the goal of selectively targeting these treatment-resistant cells, thus pioneering curative, non-toxic therapies. Group: Haemato-Oncology
+44 20 3437 6294

Biography

Professor Kamil R Kranc graduated in medicine from the Medical University of Silesia (Poland) in 2000. He then moved to the University of Oxford to obtain a DPhil in Biochemistry in 2003, followed by postdoctoral training in immunology and stem cell biology (2003-2006), and was awarded the Beit Memorial Fellowship to establish his independent group (2007-2010).

Subsequently, he took a Group Leader position at the University of Glasgow (2010-2013), followed by an appointment as Professor at the University of Edinburgh (2013-2019) and more recently at the Barts Cancer Institute in London (2018-2023).

While at Barts, Kamil held numerous leadership roles, including serving as Deputy Lead of the Centre for Haemato-Oncology and Member of the Institute’s Executive Board, particularly contributing to the faculty recruitment and their grant success. He joined ICR in December 2023.

His group's central aim is to discover novel regulators of leukaemic stem cell biology, utilising this knowledge for therapeutic benefit. To explore new avenues of translational research, for the last 15 years, Kamil has maintained collaborations with numerous experts in diverse research areas, including Professors Sir Peter Ratcliffe (hypoxia biology), Donal O’Carroll (RNA biology), Chris Schofield (biochemistry of oxygenases) and Bertie Gottgens (single cell biology).

Kamil’s group has been funded by the Beit Memorial Fellowship for Medical Research, Cancer Research UK (CRUK) Senior Fellowship, CRUK Programme Grant, as well as numerous project grants and PhD studentships from Blood Cancer UK, The Barts Charity, MRC, The Royal Society, The Wellcome, and CRUK.